Vildagliptin’s affordability will provide competitive advantage to Eris and Cipla in crowded Indian diabetes market, says GlobalData

Novartis has recently sold its anti-diabetic drug vildagliptin (branded as Zomelis, Vysov and Vysov M) to Ahmedabad-based Eris Lifesciences and Mumbai-based pharmaceutical major Cipla Ltd, in India. The orally active, potent and selective dipeptidyl peptidase -4 (DPP-4) inhibitor’s patent has expired in India leading to increased affordability of vildagliptin. Product acquisition and increased affordability of vildagliptin will provide a competitive advantage to both the companies in a market crowded with several players, says GlobalData, a leading data and analytics company.

According to GlobalData’s upcoming report, ‘Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2028’, the Indian type 2 diabetes (T2D) market, similar to other major markets, is mature and crowded with both expensive branded therapies and inexpensive generics. With an estimated diagnosed prevalent T2D population of about 90 million by 2028, approximately 80% of which are treated using anti-diabetics, India has a burgeoning T2D market with a robust and competitive pipeline.

The main drivers of market growth will be the dramatic increase in disease prevalence, and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Prashant Khadayate, Pharma Analyst at GlobalData, says: “The Indian diabetes market is highly competitive and price sensitive. Companies are always on the lookout for ways to differentiate themselves in this crowded market. Vildagliptin has shown good traction in the Indian market and patent expiry of vildaglitpin in the Indian market will increase the affordability and will lead to easier access.”

Earlier, Zomelis was sold in India by Abbott under a license from Novartis. On the other hand, Cipla was co-marketing vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (vildagliptin and metformin).

As per Q2 FY’20 results, Eris Lifesciences was ranked third in terms of the number of prescriptions within the Indian diabetology segment. In FY’19, the company’s overall leading brand Glimisave (glimepiride) generated sales of INR2,212m (US $32.5m*). Tendia (tenegliptin) and Cyblex (gliclazide) are the other leading diabetic brands of Eris Lifesciences which generated sales of INR598m (US$8.8m*) and INR396m (US$5.8m*), respectively. 

In contrast, Cipla views diabetes as a main therapeutic area of focus, due to the large market opportunity in India. In the past, the company has collaborated with Eli Lilly to market and distribute Basaglar (insulin glargine), with Janssen to market canagliflozin under brand name Prominad and with Mannkind USA to market inhaled insulin Afrezza, which is in clinical development. Cipla will be responsible to get the regulatory approval for Afrezza in India.

Khadayate concludes: “Eris Lifesciences has already emerged as one of the key players in the diabetes market through its leading brands. Sales from its diabetes portfolio makes up approximately 25% of total company sales, as witnessed in FY’19, whereas Cipla’s diabetes portfolio accounted for only 2% of total company sales in FY’18-19. However, both companies continue to be committed to bringing effective and life-changing anti-diabetic drugs to an ever-growing diabetic population in India.  in India and innovator vildagliptin brands acquisition will provide a competitive edge over the vildagliptin generics.”

*Converted currency from INR to US$ based on 2018 average rate

Real world evidence shows accelerated surgery in patients with hip fracture has substantial benefits

HAMILTON, ON, Feb. 9, 2020 /CNW/ - Canadian researchers have discovered that accelerated time to surgery – within an average of 6 hours after a hip fracture diagnosis – resulted in a lower risk of delirium and urinary tract infections, moderate to severe pain, faster mobilization, and a shorter length of hospital stay compared to standard care – when surgery occurred an average of 24 hours after a hip fracture diagnosis.

The HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial, presented on Sunday at the Orthopaedic Research Society (ORS) 2020 Annual Meeting and published in The Lancet, was led by researchers of the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences (HHS) in Hamilton, Canada. HIP ATTACK involved 2,970 people at 69 sites in 17 countries. 

Ten years ago, Dr. Devereaux - principal investigator of the HIP ATTACK trial, as well as senior scientific lead of PHRI's perioperative and surgery program, professor of medicine at McMaster, and cardiologist with HHS - was consulted to manage a 73-year-old female with a hip fracture who also had an elevated blood test (troponin) demonstrating heart injury. The referring doctor told Dr. Devereaux the patient's heart issue had to be treated before surgery for her hip fracture could occur. Despite the best of intentions, with the medical treatment Dr. Devereaux provided based on current practice at that time, the patient died before she was able to undergo surgery for her hip fracture.

Upon reflecting on this case, Dr. Devereaux wondered if the prevailing dogma regarding the need to medically optimize patients before hip fracture surgery was the wrong approach. He contacted Dr. Mohit Bhandari, co-principal investigator of HIP ATTACK and an orthopedic surgeon in Hamilton, to get his perspective on the case. Dr. Bhandari told Dr. Devereaux that observational studies suggested that shorter time to surgery may prevent death and major complications in patients with a hip fracture. Based on this evidence, they initiated a large randomized controlled trial to understand the effects of accelerated surgery in patients with a hip fracture.  

Accelerated surgery did not result in a reduction in death or a collection of major complications; however, patients randomized to accelerated surgery had a lower risk of delirium, urinary tract infection, moderate to severe pain, and were faster to stand, mobilize, and go home compared to patients randomized to standard care. Among patients who had an elevated blood test (troponin) demonstrating heart injury when they presented to the hospital with their hip fracture, accelerated surgery lowered the risk of death compared to standard care.

• "Hip fracture—as distinct from hip replacement for arthritis—is a medical emergency that kills many older people who would otherwise enjoy many more productive years of life. This study represents a decade of high-quality medical research and very committed patient partners to answer a very important practical question," said Karim Khan, Scientific Director of Canadian Institutes of Health Research Institute (CIHR) of Musculoskeletal Health and Arthritis, said. "It is now clear that in many cases, one would want to have hip fracture surgery inside 6 hours if at all possible. The challenge will be for health systems to deliver this ideal scenario. We must also remember that hip fractures can be prevented—strength and balance training work reduce falls and medication may be indicated for those at risk because of previous osteoporotic fracture."
  
  
• "Hip fractures are a common cause of presentations to over-crowded emergency departments in Canada. Many of these patients languish while awaiting surgical repair and develop complications such as delirium, over-sedation, and poor outcomes," said Dr. Brian Rowe, Scientific Director of CIHR's Institute of Circulatory and Respiratory Health and a practicing emergency physician in Edmonton. "This collaborative multi-national research, supported by a number of health funders, provides firm evidence of the need to prioritize hip surgery to improve the health of patients and reduce the burden on the health care system." 
  
  
• "Patients find waiting for hip fracture surgery undesirable because they are forced to lie flat in a bed, go without food, and they are either in pain or receiving pain medications that commonly have negative side effects," said Dr. Mohit Bhandari, co-principal investigator of HIP ATTACK and an orthopedic surgeon in Hamilton. 
  
  
• "This trial demonstrates that accelerated surgery for a hip fracture is feasible, safe, and reduces the risk of delirium, urinary tract infection, moderate to severe pain, and length of hospital stay," said Dr. Flavia Borges, the Project Officer of HIP ATTACK and a general internist in Hamilton. 
  
  
• "The lower risk of death with accelerated surgery, in patients who had evidence of a heart injury at the time of hospital admission, challenges the dogma of medical optimization before surgery. Further research should explore the benefits of accelerated surgery in this high-risk group," said Dr. P.J. Devereaux, principal investigator of the HIP ATTACK trial, as well as senior scientific lead of PHRI's perioperative and surgery program, professor of medicine at McMaster, and cardiologist with HHS.

The main funding for the HIP ATTACK trial came from the Canadian Institutes of Health Research, the Ontario Strategy for Patient Oriented Research Support Unit, and the Ontario Ministry of Health and Long-Term Care.

SOURCE Population Health Research Institute

EAT THIS “LOVE DIET” FOR A SEXY VALENTINE’S DAY

www.niketsonpal.com

As we approach Valentine’s Day, wouldn’t it be nice to know how to turn up the “heat” and make our partner’s passions go into overdrive?  One way to get those juices flowing is to use an aphrodisiac, which can be any food or drink that increases libido when consumed. Aphrodisiacs are distinct from substances that address fertility issues such as impotence or sexual dysfunction.  From the Greek word aphrodisiac, or "pertaining to Aphrodite,” the idea comes from the goddess of love. But really, is the notion of using an aphrodisiac a bit too silly to make the bedroom pop? According to Board Certified NYC Internist and Gastroenterologist Dr. Niket Sonpal, “This concept is based on science, as traditionally it is known some foods possess chemical properties that could increase pheromones and heighten our interest and others may indirectly boost testosterone or estrogen levels, thereby increasing human sex drive. Others are considered arousing because of their appearance or texture.”  In honor of Valentine's Day, Dr. Sonpal shares some of the foods commonly believed to have aphrodisiac powers.

Classically, to be considered an aphrodisiac, a substance should:

• Consumed orally
• Reliably increase libido or sexual desire (no placebo effect, no diminished libido)
• Take effect relatively immediate

The Top Aphrodisiac Delicacies 

Oysters

One of the most infamous aphrodisiacs, as their appearance mimics the labial folds of a vagina; oysters are high in zinc and have a reputation for being great for love and fertility. Researchers found that oysters contain amino acids that trigger the production of sex hormones.  Dr. Sonpal says that “Oysters offer a lean source of protein to help give you energy all night long and, in addition to offering the body zinc, which helps blood flow and nourishes sperm, there's scientific evidence that an amino acid found in oysters may directly raise sexual hormone levels."

Pistachio Nuts: These have been around for many years. They have many health benefits as they contain protein and fiber. Nevertheless, they also help to reduce symptoms of erectile dysfunction. This could be due to the fact that pistachios lower cholesterol and stimulate blood flow throughout the body.

Chai Tea

Skip the coffee after dinner and reach for a cup of Indian chai tea. The typical spices in this brew include ginger, cloves, and cinnamon, all come from exotic places and certainly will get the blood flowing, and it has almost no caffeine so the stimulant effect is less than coffee, so you'll still be able to drift off to sleep with your lover after your lovemaking!

Chili Martini: Alcohol can be a great way to calm the nerves and get into the mood provided you don’t overdo it.  Spice up your Valentine’s night with a chili martini. Thai chilies have been known to be an aphrodisiac for years because they cause your nerves to release epinephrine, which results in increased blood flow. Having a drink like this will defiantly stimulate your body and get you in the mood. 

Red Wine: If you’re not feeling bold enough to try the chili martini, why not have red wine? Red wine will be sure to leave you feeling less awkward and aroused. The scent alone has been proven to get people in the mood. It is proven that wine decreases inflammation and gets your blood pumping. 

Avocado: High levels of folic acid, vitamin B9, and B6 all provide your body with energy and even help to increase testosterone production. Food has been used throughout time to work as a way to increase sexual arousal. On top of their excellent taste, they have health and sexual benefits that could be used as a stimulant. 

Asparagus: Like many other foods, asparagus increases blood and oxygen flow due to vitamin E and potassium in it. It also tends to stimulate the urinary tract system, which causes you to have an “itch” down there which some find arousing.  

Bananas

With their phallic shape, bananas already look tempting and sensual; but they also contain bromelain, an enzyme which Dr. Sonpal says can trigger testosterone production. Its vitamin B can elevate energy levels and the high sugar content gives the brain a kick!

Chocolate

 Scientists ascribe the aphrodisiac qualities of chocolate, to two chemicals it contains. One, tryptophan, is a building block of serotonin, a brain chemical involved in sexual arousal. The other, phenylethylamine, a stimulant related to amphetamine, is released in the brain when people fall in love.

About Dr. Niket Sonpal:
Dr. Niket Sonpal is an Adjunct Assistant Professor at Touro College of Osteopathic Medicine and Clinical instructor at Kingsbrook Jewish Medical Center, Brooklyn who specializes in Gastroenterology. He is a graduate of the Medical University of Silesia – Hope Medical Institute in Poland. After completing his residency in Internal Medicine at Lenox Hill Hospital, he was selected to be the 2013‐2014 Chief Resident at Lenox Hill Hospital–Northshore LIJ Health System. Dr. Sonpal has completed his Fellowship in Gastroenterology & Hepatology at Lenox Hill Hospital and continues his work in the field of medical student and resident test preparation. He now serves as the associate program director for the Internal Medicine Residency Program at Brookdale University medical center.

He is the co‐author for the best-selling Master the Boards: USMLE Step 2 CK, Master the Boards Step 3, And Master the Boards: Internal Medicine. He is also the Chief Operating Officer for Medquest Test Prep, Director of Medical Education for Picmonic Test Prep, and a recognized expert on medical test prep.

Visual disturbances in sildenafil users

Study reports persistent visual disturbances in men taking the highest recommended dose of sildenafil, suggesting that first-time users should use a lower dose   

Sildenafil is commonly used to treat erectile dysfunction and is generally regarded as safe with limited side effects. However, a recent study in Frontiers in Neurology has highlighted the risk of persistent visual side-effects, such as light sensitivity and color vision impairment, in men who have taken the highest recommended dose of sildenafil. While these effects appear to be rare, the research suggests that first-time sildenafil users should start with a lower dose before increasing it, if necessary.

Erectile dysfunction can have significant psychological consequences for men who are affected by it, and it can make fulfilling sexual relationships more difficult to achieve. Sildenafil became available in 1998 as a treatment for erectile dysfunction. It soon became the fastest selling drug in history, demonstrating the phenomenal demand for treatments that enhance sexual performance.

Originally developed as a treatment for high blood pressure, the drug dilates blood vessels and relaxes smooth muscle in the penis, making it easier to achieve and maintain an erection. The effects of the drug normally last 3–5 hours and although side-effects such as headache and blurred vision occasionally occur, they usually disappear relatively quickly.

However, Dr. Cüneyt Karaarslan of the Dünyagöz Adana hospital in Turkey, noticed a pattern in 17 male patients who attended the hospital. In the new study, Karaarslan reports that the patients suffered numerous visual disturbances, including abnormally dilated pupils, blurred vision, light sensitivity, and color vision disturbances, which included intensely blue colored vision with red/green color blindness.

All 17 patients had taken sildenafil for the first time, and all took the highest recommended dose of 100 mg. None of the men had been prescribed the medication. The visual side-effects began once the drug took effect, and were still present when the men arrived at the clinic 24-48 hours later.

The doctors in the clinic conducted various eye tests and monitored the patients over time to see how their symptoms developed. Fortunately, in all 17 patients the symptoms had cleared up by 21 days later, but this was doubtless a difficult experience for the men involved.

“Many men use non-prescription performance enhancing drugs to help with sexual anxiety and erectile dysfunction,” said Karaarslan. “For the vast majority of men, any side-effects will be temporary and mild. However, I wanted to highlight that persistent eye and vision problems may be encountered for a small number of users.”

So, why were these men susceptible to such long-lived side-effects? It may be possible that a small subsection of the population does not break sildenafil down and eliminate it from the body efficiently, leading to very high concentrations in the blood compared with most users.

These men also took the highest recommended dose of sildenafil on their first time taking the drug. Starting with a lower dose may have meant less severe side-effects. In addition, taking the drug under medical supervision would likely have meant that the men would not have used such a high dose on their first time. 

So, if you are struggling with erectile dysfunction, should you be worried about trying sildenafil? In short, no. Such persistent side-effects appear to be very rare. However, it is always best practice to consult your physician first, it may be best not to start at the highest dose, and in case you are particularly sensitive, consider first using the drug under medical supervision.

“Although these drugs, when used under the control of physicians and at the recommended doses, provide very important sexual and mental support, uncontrolled and inappropriate doses should not be used or repeated,” said Karaarslan.

Toning and sculpting arms is an important part of any workout regimen. Those prominent arm muscles are not only a great way to show off your hard work but also boost your performance in many sports. However, arms are also one of the more delicate and injury-prone parts of your body. Read on to learn about four common arm injuries and how to treat and prevent them.

Rotator Cuff Tear

The rotator cuff is a group of muscles and tendons that assist with lifting and rotating your arm. These muscles and tendons often tear during throwing sports like baseball and basketball or while lifting weights. Mild to moderate tears are treated with rest, pain medications and physical therapy, while a severe injury may require surgery. Prevent a rotator cuff tear with proper stretching before working out and using good form when lifting weights or playing sports.

Bicep Tendonitis

Many fitness fanatics want bulging biceps to show off, but overworking this muscle can lead to painful inflammation called tendonitis. Bicep tendonitis is treated by using an upper arm sleeve to compress the muscle and NSAID medications like ibuprofen or naproxen to reduce inflammation. To avoid this injury, stretch and warm up your biceps before working out and don’t lift more weight than you can handle.

Sprained Wrist

Wrist sprains are a common result of catching yourself with outstretched arms during a fall. Most sprains are mild and heal with a week or two of rest, ice and compression. However, severe sprains may require weeks of immobilization followed by physical therapy. If you participate in an activity like ice skating or gymnastics where falls are common, learn how to fall with proper technique to prevent wrist sprains. Wearing wrist supports while working out can also help.

Tennis Elbow

You don’t have to play tennis to get tennis elbow. This repetitive strain injury to the elbow and forearm causes inflammation and loss of mobility and is treated with rest, immobilization and physical therapy. Severe cases may require orthotic devices or surgery. Reduce your risk of tennis elbow by taking a break if you feel soreness and using exercises to build strength in your forearms.

Do you suffer from repeated arm, wrist and shoulder injuries? Sustaining the same injury over and over is a sign that you need to improve your workout technique. Consider working with an experienced trainer or physical therapist to learn how to exercise without straining your body or injuring yourself.

Breakthrough in Body Contouring Makes National Debut at Offices of Renown Miami Based Plastic Surgeon,

Dr. Adam J. Rubinstein, MD, FACS

February 2020—Miami, Florida -- Board-certified, Miami plastic surgeon, Dr. Adam J. Rubinstein, MD, FACS, announces the national debut of EON FR (Fat Reduction).  EON FR technology for body contouring is the world’s first non-invasive, non-contact body sculpting devise that is FDA cleared for abdominal fat reduction.  EON FR is unique, innovative and 100% safe, effectively delivering laser energy to treat the adipose tissue for fat reduction and body sculpting with no fuss, no pain, no post-treatment massages and no patient down time!

Unlike other non-invasive fat reduction procedures, EON FR takes about 15 minutes and treats 6x more surface area than the market leader. EON FR does not require applicators or gels. Before performing the treatment, Dr. Rubinstein determines the area for body contouring then the EON FR maps the patient’s topography. It actually scans and adjusts to the exact shape of the patient’s body. The new device uses an articulated robotic arm that delivers laser energy to the targeted area while patient comfort is maintained with a patent-pending cooling system. Laser energy from EON FR induces apoptosis, a process in which the body naturally eliminates fat cells through its lymphatic system with optimal results seen after just 12 weeks. In a clinical study, all patients received an average fat reduction of 15.1% and over 39% achieved between 20—45% fat reduction in a single treatment. “The is truly 21^st century tech. Non-contact, robotics, state of the art cooling, it has everything a patient would want.” says Dr Adam Rubinstein.  “EON FR  offers a pain-free treatment that is customized to the patient’s body and completed comfortably in 15 minutes. This is a huge breakthrough. I’m proud to be among the first to offer this to my patients,” he adds.

About Dr Adam J. Rubinstein

Dr Adam J. Rubinstein is a Board Certified and Award-Winning Plastic Surgeon. He has served as the Chief of Plastic Surgery and Chief of the Department of Surgery for Jackson North Medical Center in Miami, FL. Dr Rubinstein specializes in whole body surgical & non-surgical cosmetic treatments for both women and men.  He can discuss the latest innovations and procedures to help people make proper and informed choices.  Dr. Rubinstein is also a patient advocate and is passionate about sharing the good, the bad and the ugly about common plastic surgery practices to help patients navigate the world of plastic surgery effectively and safely.  His goal is to help people make their best choices about the latest and most innovative procedures.  He is also an outspoken patient advocate and believes people have the right to know to make informed choices.  You can learn more on his social channels including his Instagram accounts, @drrubinstein and @plasticsurgerytruths, SnapChat @drrubinstein, and Facebook page @MiamiPlasticSurgeon. www.dr-rubinstein.com

About Eon

EON FR’s body contouring technology is fast, easy to use, and covers a larger surface area. Dominion develops disruptive aesthetic technologies to meet the needs of aesthetic physicians.

Dominion Aesthetic Technologies, Inc. (Dominion) is a laser platform medical device company headquartered in San Antonio, TX, with technical labs in Orlando, Fl.

Dominion’s product EON FR, the world’s first non-invasive, non-contact body contouring device is FDA cleared for full abdominal fat reduction (FR).

The company’s purpose is to offer the best solutions for aesthetic physicians and practitioners. In developing new products, it utilizes the knowledge of its Scientific Advisory Committee comprised of world-renowned experts. The company designs, builds and commercializes high technology aesthetic devices.

EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)

This decision brings ^PrMAVENCLAD® (cladribine tablets) closer to broader access for eligible patients living with Relapsing-Remitting Multiple Sclerosis in the province of Quebec

MISSISSAUGA, ON, Feb. 6, 2020 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that it received a positive recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for MAVENCLAD (cladribine tablets). MAVENCLAD was approved by Health Canada in November 2017 as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability.ⁱ

With the positive assessment of the therapeutic value of MAVENCLAD from INESSS to Quebec's Minister of Health and Social Services, EMD Serono will now work with the Ministère de la Santé et des Services sociaux to include MAVENCLAD on the Régie de l'assurance maladie du Québec (RAMQ) List of Medications.  Once included on the RAMQ List of Medications, eligible patients living in the province of Quebec will have equitable access to MAVENCLAD as a treatment option for RRMS, which is currently reimbursed by most private drug insurance plans.  

"We are delighted with the positive recommendation from INESSS, which recognizes the therapeutic value of MAVENCLAD and the need for this treatment option for eligible patients who live with RRMS," said Gaby Murphy, President & Managing Director, EMD Serono, Canada. "We welcome this as an important step to ensure broader and equitable access to MAVENCLAD in the province of Quebec."

"Some 20,000 people in Quebec alone are living with MS, and the INESSS recommendation for MAVENCLAD is great news for patients," said Louis Adam, Executive Director of the Quebec and Atlantic Division of the MS Society of Canada. "Having access to new and innovative treatment options is important for people living with MS in the province of Quebec, and we are delighted by this positive step forward." 

Canada has one of the highest rates of MS in the world, with one in 385 people living with the disease.ⁱⁱ EMD Serono, Canada is deeply committed to people living with MS, and to leading innovation within the MS space. 

About MAVENCLAD 
MAVENCLAD (cladribine tablets) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS.ⁱⁱⁱ In November 2017, Health Canada approved MAVENCLAD (cladribine tablets) as monotherapy for the treatment of adult patients with RRMS to reduce the frequency of clinical exacerbations and delay the progression of disability. MAVENCLAD is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis. 

MAVENCLAD has been approved in over 70 countries including the United States, European Union (EU), Australia and Switzerland, for various relapsing MS indications. 

The clinical development program of MAVENCLAD in MS comprises more than 12,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. These clinical trials include the Phase III CLARITY, CLARITY extension and ORACLE MS trials, the Phase II ONWARD trial and the PREMIERE Long-term Safety Registry.

About Multiple Sclerosis
Multiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged.^iv It is estimated that approximately 2.3 million people have MS worldwide.^vCanada has one of the highest rates of MS in the world with one in 385 people living with the disease.^vi While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes.^vii The relapsing forms of MS are the most common type at the time of diagnosis.^viii

About EMD Serono, Canada
EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Ontario.

About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

______________________________

SOURCE EMD Serono, Canada

For further information:

or to arrange an interview, please contact: Hibaq Ali, Weber Shandwick Canada, 416.642.7915, hali@webershandwick.com; Smita Devane-Bhan, Associate Director of Communications, EMD Serono Canada, 905.483.3860, smita.devane-bhan@emdserono.com

BioSteel Named Official Sports Drink of the Brooklyn Nets and Barclays Center

BROOKLYN, NY, Feb. 6, 2020 /CNW/ - BioSteel Sports Nutrition Inc. ("BioSteel") has been named The Official Sports Drink of the Brooklyn Nets and Barclays Center, the company's first major partnership with a professional U.S. sports team. 

The multi-year agreement includes significant BioSteel branding at Barclays Center for all Nets games, as well as signage integrated at HSS Training Center, the Nets' state-of-the-art practice facility in Brooklyn. Integration at these facilities will incorporate a variety of elements such as digital and static signage throughout the venues, including the media backdrops, and the centerhung scoreboard at Barclays Center. In the second year of the partnership, BioSteel will receive branding on the Nets' and visiting teams' benches during all of the team's home games. 

Founded in 2009, BioSteel's focus on premium natural ingredients, product transparency, and identifying the essential nutrients needed to power physical activity has led to the brand achieving a reputation for being the hydration product provider of choice for high-performance athletes.

"The Brooklyn Nets have been using BioSteel products for years, and becoming our official sports drink partner is a natural evolution of our relationship," said Bryan Calka, Senior Vice President of Global Partnerships at BSE Global. "Sports nutrition is of the utmost importance to our team, and we are looking forward to expanding our work with BioSteel as it continues to lead the way in nutritional support for athletes everywhere."

"We commend the Brooklyn Nets for making a healthy choice by partnering with a sugar-free sports drink company," said Co-CEO, Co-Founder, and former NHLer, Michael Cammalleri. "With this alliance, BioSteel tips off one of many major US-based marketing initiatives that we will be rolling out this year as we rapidly expand our presence in the United States." 

Originally formulated for professional athletes, BioSteel's products have gained mainstream popularity due to the authenticity of the brand's partnerships and the quality and efficacy of its products. This relationship allows BioSteel to continue to tell an authentic story that started in the locker room and is now spilling over to the mass retail market. 

ABOUT BIOSTEEL
BioSteel is a North American operated sports nutrition company that was built on the mandate of providing the safest, healthiest, and most effective line of nutritional products available. BioSteel's line of nutritional products ranges from a sugar and caffeine free sports beverage with no artificial flavors, colors, or preservatives, to a line of proteins and everyday essentials. BioSteel products are currently readily available across North America, and globally with select retail partners or direct to consumers online, through www.biosteel.com.

ABOUT BSE GLOBAL
BSE Global manages and operates Barclays Center, the Brooklyn Nets, its NBA G League team, the Long Island Nets, and its NBA 2K League affiliate, NetsGC. The company also includes the WNBA's New York Liberty. Through programming, marketing, sales, and operations, BSE Global delivers dynamic content and experiences for audiences.

SOURCE BioSteel Sports Nutrition Inc.

Survivors in Canada are Taking Steps to Reduce the Risk of Another Heart Attack. But is it Enough?

New Amgen Survey Shows Heart Attack Survivors in Canada Do Not Know Their Cholesterol Level or What It Should Be 

MISSISSAUGA, ON, Feb. 6, 2020 /CNW/ - In recognition of February as Heart Month, Amgen Canada ("Amgen") today released Canadian findings as part of a global survey¹ that evaluated worldwide heart attack survivors' perceptions and awareness of the connection between cholesterol and cardiovascular (CV) events revealing that 56 per cent of respondents in Canada do not consider high cholesterol to be a chronic condition requiring long-term management and care.²

Low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, is one of the most important modifiable risk factors for heart attack.³ Globally more than 40% of patients who have had a CV event, like a heart attack, will go on to have another within two years.⁴

The survey's findings show that while heart attack survivors are proactively trying to improve their cardiovascular health, they may not fully understand the importance of lowering high LDL-C to reduce their risk of another heart attack: 

• Sixty-two per cent of survey respondents report being mindful about what they eat, 60 per cent monitor their blood pressure and 55 per cent are conscious of their weight.⁵
• However, confusion remains when it comes to lowering cholesterol. Only one in two heart attack survivors know both their current and target cholesterol level; and of survivors living with high cholesterol, 88 per cent do not consider it to be a leading risk factor for another event.⁶

"Cardiovascular disease remains one of the most significant health challenges in Canada where an estimated 63,200 adults will experience a first heart attack this year⁷," said Ponda Motsepe-Ditshego, Executive Medical Director at Amgen Canada. "This survey shows patients want to reduce their risk of another heart attack, but are unsure about the best actions to take. This Heart Month we're urging high-risk patients to talk to their doctor and learn more about the connection between high cholesterol and the risk of a repeat heart attack as well as how they can lower their cholesterol levels."

The survey of more than 3,200 heart attack survivors across 13 countries, including 250 people in Canada – revealed that patients might not be having the right conversations with their doctors. Additional key findings included:

• Fifty-six per cent of surveyed Canadians do not believe high cholesterol is a chronic condition requiring long-term care.²
• While 88 per cent of patients have had their cholesterol checked in the last year by a physician, only six out of ten patients have discussed the role of cholesterol in heart attacks with their healthcare professional.⁶

Globally, approximately 8 of 10 very high-risk adults are still unable to attain their LDL-C goal despite lipid-lowering therapy.⁸Professional cardiology societies around the world now recognize that lower cholesterol reduces the risk of another CV event, which is reflected in updated treatment guidelines for high-risk patients. Newer, more potent treatment options are the only way for these high-risk patients to achieve recommended cholesterol levels that can help reduce their risk of another heart attack.

Amgen encourages heart attack survivors or anyone concerned about their cardiovascular health to spend this Heart Month learning about cholesterol. But a heart-healthy lifestyle is an ongoing process, so talk to your doctor to learn more about how you can improve your heart health and reduce your risk of life-changing CV events.

About the Survey

The research was commissioned by Amgen and conducted by KRC Research, an independent global public opinion research consultancy. A total of 3,236 online surveys were completed by post-myocardial infarction (MI) patients aged 40 or older in 13 different countries. Two hundred and fifty heart attack survivors were surveyed in Canada. Participating countries included the United States, Mexico, Brazil, Canada, United Kingdom, France, Germany, Spain, Italy, the Netherlands, China, South Korea, and Japan. The survey included approximately 250 MI patients from each participating country. Data collection took place from June 21 to July 18, 2019. 

About Heart Month

February is Heart Month, a time to bring attention to the importance of cardiovascular health, and what we can do to reduce our risk of cardiovascular disease.⁹

Heart disease affects approximately 2.4 million Canadian adults, and is the second leading cause of death in Canada.¹⁰

About Amgen Canada

As a leader in innovation, Amgen Canada understands the value of science. With main operations located in Mississauga, Ont.'s vibrant biomedical cluster, and its research facility in Burnaby, B.C., Amgen Canada has been an important contributor to advancements in science and innovation in Canada since 1991. The company contributes to the development of new therapies and new uses for existing medicines in partnership with many of Canada's leading health-care, academic, research, government and patient organizations. To learn more about Amgen Canada, visit www.amgen.ca.

References

SOURCE Amgen Canada